ArticleDiscover oncology2025
An integrative bioinformatic and Mendelian randomization study exploring the role of polyunsaturated fatty acid metabolism in laryngeal cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to explore potential associations between polyunsaturated fatty acid (PUFA) metabolism and laryngeal cancer (LC) using a combination of Mendelian randomization (MR) and integrative bioinformatics, while investigating its potential immunogenic implications.
methodsTranscriptomic data from the GEO database were integrated to identify differentially expressed genes (DEGs) in LC. Gene Set Enrichment Analysis (GSEA) was performed in addition to Gene Ontology and KEGG enrichment analyses to characterize biological functions. MR analysis was employed to assess the potential causal link between PUFA metabolism and LC risk. PUFA-associated genes were screened for druggability using the DGIdb database. Furthermore, an lncRNA-miRNA-mRNA (ceRNA) regulatory network was constructed, and immune cell infiltration in LC was profiled using CIBERSORT with LM22 signature matrix to uncover immunoregulatory associations with PUFA pathway genes.
resultsA total of 730 DEGs were identified from a combined cohort of 30 LC and 31 normal samples. GSEA and enrichment analysis revealed significant involvement in fatty acid metabolism and immune-related pathways. MR analysis demonstrated a statistically significant but modest association between PUFA metabolism and LC risk (OR = 0.9996, 95% CI = 0.9992-0.9999, p = 0.020). A network of key PUFA pathway genes (e.g., ADH1B, ADH1A, ALDH7A1, CYP2J2, PTGIS) was linked with multiple drug targets. A focused sub-network of regulatory interactions among lncRNAs, miRNAs, and mRNAs was elucidated. Immune infiltration analysis revealed distinct correlations between pathway gene expression and immune cell populations, particularly showing PTGIS positively correlated with activated mast cells and negatively with naive B cells.
conclusionsOur findings suggest a potential mechanistic link between PUFA metabolism and LC susceptibility, generating hypotheses that PUFA-associated pathways may modulate immune microenvironment characteristics. This computational study provides preliminary insights into potential immunometabolic therapeutic strategies in laryngeal cancer that warrant experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.